Synthetic Biologics Announces Phase I Study To Evaluate The Safety, Tolerability, And Efficacy Of VCN-01 In Combination With Durvalumab In Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma Of The Head And Neck Was Presented At The ESMO Congress